A novel selective small-molecule PI3K inhibitor is effective against human multiple myeloma in vitro and in vivo.

A novel selective small-molecule PI3K inhibitor is effective against human multiple myeloma in vitro and in vivo.

Item
http://www.wikidata.org/entity/Q42959293
Novel agents in the treatment of multiple myeloma: a review about the futureTherapeutic targeting of cancers with loss of PTEN function.In-vitro and in-vivo combined effect of ARQ 092, an AKT inhibitor, with ARQ 087, a FGFR inhibitor.A virtual screen identified C96 as a novel inhibitor of phosphatidylinositol 3-kinase that displays potent preclinical activity against multiple myeloma in vitro and in vivoFirst-in-human phase I study of copanlisib (BAY 80-6946), an intravenous pan-class I phosphatidylinositol 3-kinase inhibitor, in patients with advanced solid tumors and non-Hodgkin's lymphomas.Kinase inhibitors as potential agents in the treatment of multiple myeloma.Systemic modeling myeloma-osteoclast interactions under normoxic/hypoxic condition using a novel computational approachEfficacy of phosphatidylinositol-3 kinase inhibitors with diverse isoform selectivity profiles for inhibiting the survival of chronic lymphocytic leukemia cells.Feedback suppression of PI3Kα signaling in PTEN-mutated tumors is relieved by selective inhibition of PI3Kβ.The novel PI3 kinase inhibitor, BAY 80-6946, impairs melanoma growth in vivo and in vitro.Emerging treatment approaches for myeloma-related bone disease.Distinct roles of class I PI3K isoforms in multiple myeloma cell survival and dissemination.Copanlisib: First Global Approval.A preclinical evaluation of the PI3K alpha/delta dominant inhibitor BAY 80-6946 in HER2-positive breast cancer models with acquired resistance to the HER2-targeted therapies trastuzumab and lapatinib.Novel phosphatidylinositol 3-kinase inhibitor BKM120 enhances the sensitivity of multiple myeloma to bortezomib and overcomes resistance.Copanlisib for treatment of B-cell malignancies: the development of a PI3K inhibitor with considerable differences to idelalisib
P2860

A novel selective small-molecule PI3K inhibitor is effective against human multiple myeloma in vitro and in vivo.

Item
http://www.wikidata.org/entity/Q42959293
description
2013 nî lūn-bûn
@nan
2013年の論文
@ja
2013年論文
@yue
2013年論文
@zh-hant
2013年論文
@zh-hk
2013年論文
@zh-mo
2013年論文
@zh-tw
2013年论文
@wuu
2013年论文
@zh
2013年论文
@zh-cn
name
A novel selective small-molecu ...... myeloma in vitro and in vivo.
@en
A novel selective small-molecu ...... myeloma in vitro and in vivo.
@nl
type
label
A novel selective small-molecu ...... myeloma in vitro and in vivo.
@en
A novel selective small-molecu ...... myeloma in vitro and in vivo.
@nl
prefLabel
A novel selective small-molecu ...... myeloma in vitro and in vivo.
@en
A novel selective small-molecu ...... myeloma in vitro and in vivo.
@nl
P1433
P1476
P2093
P2860
P2888
P304
P31
P356
P478
P577
P5875
P6179
P698
P932
P356
P1433
P1476
A novel selective small-molecu ...... myeloma in vitro and in vivo.
@en
P2093
P2860
P2888
P304
P31
P356
P478
P577
P5875
P6179
P698
P932